Is an Anti-Aging Drug Around the Corner?
Joan Mannick, resTORbio and David Rotman, MIT Technology Review
September 18, 2019 | EmTech
Joan Mannick, Cofounder and Chief Medical Officer, resTORbio
Dr. Joan Mannick is cofounder and Chief Medical Officer of resTORbio, where she spearheads the clinical program to develop a new class of innovative medicines that target the biology of aging to prevent or treat age-related diseases. Previously, Dr. Mannick was Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research, where she led a clinical program targeting a new approach to treat aging-related diseases. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme and a faculty member at Harvard Medical School and University of Massachusetts Medical School. Dr. Mannick received her AB from Harvard College and her MD from Harvard Medical School.
David Rotman, Editor at Large, MIT Technology Review
David Rotman is the editor of MIT Technology Review. He supervises editorial for both the print magazine and the website. A science and business journalist, he has written extensively on chemistry, biotechnology, materials science, and environmental issues. He joined MIT Technology Review in January 1998 as a senior editor covering nanotechnology. Before joining MIT Technology Review, Rotman was managing senior editor at Chemical Week magazine in New York City, where he supervised coverage of technology, research, and environmental issues. He has a BS degree from the University of Massachusetts in Amherst.
Please enter your email address to view this free video.
We'd like to keep in touch about future MIT Technology Review initiatives and events.